Education
About Us
Working with TipRanks
Follow Us
Acrux Limited (AU:ACR)
ASX:ACR
ACR Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume88.57K
Average Volume (3M)438.33K
Market Cap
$6.96M
Enterprise ValueAU$6.15M
Total Cash (Recent Filing)$3.33M
Total Debt (Recent Filing)AU$2.11M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Aug 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 18, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding409,263,520
10 Day Avg. Volume305,577
30 Day Avg. Volume438,335
Financial Highlights & Ratios
PEG Ratio0.90
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Acrux News
PremiumCompany Announcements
Acrux Secures $0.46 Million Advance on FY25 R&D Tax Incentive
PremiumCompany Announcements
Acrux Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Acrux Limited Sees Change in Substantial Shareholding
PremiumCompany Announcements
Acrux Ltd Appoints New Director with No Prior Securities Interest
PremiumCompany Announcements
Acrux Director Increases Stake with New Share AcquisitionPremiumCompany Announcements
Acrux Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Acrux Launches Innovative Dapsone Gel in U.S. MarketPremiumCompany Announcements
Acrux Limited Appoints John Warmbrunn as New CEOOptions Prices
Currently, No data available
---
Ownership Overview
4.90% Insiders
―
Mutual Funds
― Other Institutional Investors
95.10% Public Companies and
Individual Investors
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.08 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is $6.96M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 22, 2025 which is in 34 days.
How were Acrux Limited’s earnings last quarter?
Currently, no data Available
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 409,263,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:ACR Sentiment 66%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-87.27%
12-Months-Change
Fundamentals
Return on Equity
-132.58%
Trailing 12-Months
Asset Growth
-41.17%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Technical Analysis
Living Cell Technologies
―
Invex Therapeutics Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―